Nanobiotix announces new results from a phase 1 study evaluating JNJ-1900 (NBTXR3) (10.20 +0.46)
- Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1.
- Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV).
- 47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.1.
- 78.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.1.
- 14.6 months median Overall Survival (mOS) in all patients treated (n=21).
- Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1.
- Co will host a conference call to discuss the data on September 18, 2025 at 8:00AM EDT/ 2:00PM CEST.